tiprankstipranks
Hutchmed reports FY24 EPS 22c vs. 59c last year
PremiumThe FlyHutchmed reports FY24 EPS 22c vs. 59c last year
2M ago
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
Premium
The Fly
Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab
2M ago
Hutchmed completes enrollment of fanregratinib trial
Premium
The Fly
Hutchmed completes enrollment of fanregratinib trial
3M ago
Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
PremiumThe FlyMorning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
5M ago
Hutchmed announces NDA acceptance in China, payment from AstraZeneca
Premium
The Fly
Hutchmed announces NDA acceptance in China, payment from AstraZeneca
5M ago
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
Premium
The Fly
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
5M ago
Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial
PremiumThe FlyHutchmed announces new, updated data from sovleplenib ESLIM-01 trial
7M ago
Hutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales
Premium
The Fly
Hutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales
7M ago
Hutchmed announces results from SAVANNAH trial
Premium
The Fly
Hutchmed announces results from SAVANNAH trial
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100